Aps Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 30.18%
- Profit Growth 191.65%
- Ebitda 3969.81%
- Net Worth 174.82%
- Total Assets 56.36%
About Aps Drugs
Aps Drugs Private Limited (ADPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 June 2017 (Seven years and eight months 24 days old ). Its registered office is in Kolkata, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Pradip Sachan, Shalini Sachan, and Biswanath Bag serve as directors at the Company.
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909WB2017PTC221313
- Company No.
221313
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jun 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Aps Drugs?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pradip Sachan  | Director | 01-Jun-2017 | Current |
| Shalini Sachan | Director | 01-Jun-2017 | Current |
| Biswanath Bag | Additional Director | 24-Apr-2018 | Current |
Financial Performance of Aps Drugs.
Aps Drugs Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 30.18% increase. The company also saw a substantial improvement in profitability, with a 191.65% increase in profit. The company's net worth Soared by an impressive increase of 174.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aps Drugs?
Unlock access to Aps Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Aman Drugs Private LimitedPradip Sachan and Shalini Sachan are mutual person
Psa Drugs LlpPradip Sachan and Shalini Sachan are mutual person
- Lunaris Pharma Private Limited
Pradip Sachan and Shalini Sachan are mutual person
- Avenue Pharma Private Limited
Pradip Sachan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aps Drugs?
Unlock and access historical data on people associated with Aps Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aps Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aps Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.